Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by fredgoodwinsonon Aug 04, 2020 9:40am

183 Views

Post# 31360242

RE:RE:RE:RE:RE:RE:RE:Secret

Hank I should qualify that in respect of 'other super compounds' as the original ann in that respect did not specify whether it was a metal-based compound or if so which metal but in Sherri`s area of expertise it is very likely so and to be honest the Osmium compound just announced looks to fall into that category:

‘Here we introduce an Os(II)-based PS (Os-4T) that is extremely potent, can be activated with near-infrared light (NIR, 733 nm), and exhibits photocytotoxic effects in hypoxia (1% O2). To our knowledge, this complex is the first hypoxia-active Os(II)-based PS and it exhibits one of the largest PIs that we have encountered to date.’

Bullboard Posts

Soma Gold poised to extend profitable track record